Alpha 2.0
Login Register
» Authors » Pieter Van Remoortere

Pieter Van Remoortere

Explore the profile of Pieter Van Remoortere including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 269
Followers 0
Related Specialties
Pharmacology
Infectious Diseases
Microbiology
Top 10 Co-Authors
Jan Rosier
Piet Wigerinck
Lieven Baert
Christian Schwabe
Laurent Schueller
Leen Vijgen
Thomas N Kakuda
Elke Van Gyseghem
Guy Van den Mooter
Gerben van t Klooster
Published In
Antivir Ther
J Med Chem
Bioorg Med Chem Lett
Eur J Pharm Biopharm
Antimicrob Agents Chemother
Affiliations
Soon will be listed here.
Recent Articles
1.
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults
Pierson W, Tuefferd M, Herschke F, Slaets L, Crabbe M, Verstappen D, et al.
Antivir Ther . 2023 May; 28(3):13596535231172878. PMID: 37199270
Background: Chronic hepatitis B (CHB) is responsible for major disease burden worldwide. However, the number of available therapies is limited; cure remains an elusive goal. JNJ-64794964 (JNJ-4964) is an oral...
2.
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants
Wu L, Hu Y, Gane E, Slaets L, De Creus A, Ding Y, et al.
Antivir Ther . 2023 Jan; 28(1):13596535231151626. PMID: 36691849
Background: JNJ-4964 is a TLR7 agonist, which, via a type I interferon (IFN)-dependent mechanism, may enhance host immunity suppressed by persistent exposure to hepatitis B antigens in chronic hepatitis B....
3.
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers
Kakuda T, Yogaratnam J, Westland C, Gane E, Schwabe C, Vuong J, et al.
Antivir Ther . 2022 Apr; 26(1-2):13-24. PMID: 35485346
Background: Pharmacokinetics and safety of JNJ-64530440, a hepatitis B virus capsid assembly modulator producing normal empty capsids (CAM-N), in healthy volunteers were evaluated. Methods: This Phase I study (NCT03439488) was...
4.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults
Gane E, Pastagia M, Schwertschlag U, De Creus A, Schwabe C, Vandenbossche J, et al.
Antivir Ther . 2022 Apr; 26(3-5):58-68. PMID: 35485332
Background: This Phase I, two-part, first-in-human study assessed safety/tolerability and pharmacokinetics/pharmacodynamics of single-ascending doses (SAD) and multiple doses (MD) of the oral toll-like receptor-7 agonist, JNJ-64794964 (JNJ-4964) in healthy adults....
5.
Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection
Gane E, Schwabe C, Berliba E, Tangkijvanich P, Jucov A, Ghicavii N, et al.
J Antimicrob Chemother . 2022 Jan; 77(4):1102-1110. PMID: 35040959
Objectives: We investigated JNJ-64530440 (a hepatitis B virus capsid assembly modulator) safety, antiviral activity and pharmacokinetics in patients with chronic hepatitis B (CHB) (Phase 1b, NCT03439488). Methods: Twenty treatment-naive, HBeAg-positive...
6.
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study
Lawitz E, Poordad F, Gutierrez J, Beumont M, Beets G, Vandevoorde A, et al.
Health Sci Rep . 2020 Apr; 3(2):e145. PMID: 32270053
Background And Aims: Direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment....
7.
Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study
Yogaratnam J, Rito J, Kakuda T, Fennema H, Gupta K, Jekle C, et al.
J Infect Dis . 2018 Jul; 219(2):177-185. PMID: 30053042
Background: AL-794 is an orally active prodrug of ALS-033719, which selectively inhibits the endonuclease domain of influenza virus A and B polymerase. Methods: In a phase 1, double-blinded, randomized, placebo-controlled...
8.
Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults
Kakuda T, Yogaratnam J, Rito J, Boyce M, Mitchell T, Gupta K, et al.
Antivir Ther . 2018 Jun; 23(7):555-566. PMID: 29927386
Background: This double-blind, first-in-human Phase I study evaluated pharmacokinetics, safety and tolerability of AL-794 (prodrug of ALS-033719), a potent endonuclease inhibitor of influenza A and B in healthy volunteers. Methods:...
9.
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen
Bourgeois S, Horsmans Y, Nevens F, Van Vlierberghe H, Moreno C, Beumont M, et al.
Antimicrob Agents Chemother . 2017 Oct; 61(12). PMID: 28971875
Interactions between simeprevir (hepatitis C virus [HCV] NS3/4A protease inhibitor) and ledipasvir (HCV NS5A replication complex inhibitor) were investigated in treatment-naive HCV genotype 1-infected patients without cirrhosis, treated with simeprevir-sofosbuvir-ledipasvir...
10.
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845
Vijgen L, Thys K, Vandebosch A, Van Remoortere P, Verloes R, De Meyer S
Virol J . 2017 Jun; 14(1):101. PMID: 28569206
Background: In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high sustained virologic response 12 ...